Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Inclusion Criteria: * Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL * Fasting mean TG level ≤400 mg/dL * Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20 mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or pravastatin (10, 20 or 40 mg daily) Exclusion Criteria: * Clinically significant cardiovascular disease within 12 months of screening * Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued * Type 1 diabetes or uncontrolled type 2 diabetes * Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening * History of chronic musculoskeletal symptoms such as fibromyalgia * Uncontrolled hypothyroidism * Liver disease or dysfunction * Renal dysfunction or nephritic syndrome * Gastrointestinal conditions or procedures or surgeries * Hematologic or coagulation disorders or low hemoglobin levels * HIV or AIDS * History of malignancy * History of drug or alcohol abuse within 2 years * Use of experimental or investigational drugs within 30 days of screening * Use of ETC-1002 in a previous clinical study